A research team from the University of Delaware sought to see how much strength one would need, how fast they needed to walk, and how far they needed to walk to achieve a sufficient 6,000 steps in a day, and found that most knee OA patients surpassed their thresholds.
Researchers who evaluated adverse events in a large sample of patients taking NSAIDs for arthritis came to a surprising conclusion: celecoxib is the safest of three drugs studied.
Speaking at ACR 2016, the current chair of the Spondyloarthritis Research and Treatment Network (SPARTAN) presented data that showed that a combination of inflammatory drugs may inhibit ankylosis, the painful fusion of bones.
Certain types of inflammation go hand-in-hand. Columbia University researchers hypothesized that treatment that lowered arthritis disease activity would also decrease the risk of heart failure.
Biologics might have revolutionized treatment for rheumatoid arthritis, but they can increase the risk of serious infections or hospitalizations in some patients.
The lack of progress in new treatments for lupus nephritis summarized in this scientific review.
The American College of Rheumatology and the European League Against Rheumatism have published an international set of classification criteria for primary Sjögren's syndrome.
Approved by the FDA to treat plaque psoriasis, psoriatic arthritis, and active Crohn's disease, ustekinumab appeared to benefit patients with severe atopic dermatitis (AD) in a small study seeking to correlate its immunologic effects with clinical efficacy.
Patients with moderate-to-severe psoriasis who switch biologic medications at the end of a clinical trial should go through an induction period.
The MD Magazine editors rounded up the 10 best stories from October – did you read them all?
Medical misinformation is abundant online. The president and co-founder of the Global Healthy Living Foundation and CreakyJoints offers rheumatologists some tips with Dr. Google.
Sticks and stones may break my bones, but so could regular cannabis use, according to a study from The University of Edinburgh.
Researchers rank febuxostat as the most effective urate-lowering drug for reaching serum uric acid targets for gout patients.
Fibromyalgia is notoriously difficult to diagnose. But a new study from the University of Colorado Boulder (CU Boulder) may have found a brain signature that red flags the disease.
Experts now believe that psoriatic arthritis should be considered a risk factor for cardiovascular diseases, including stroke.
Cryptococcal meningitis infections in systemic lupus erythematosus (SLE) patients often go misdiagnosed, researchers find.
Gastrointestinal involvement is known to be associated with primary vasculitis. But in some cases, it may be IBD with secondary vasculitis, this review shows.
When a patient presents with a history of Lyme disease and joint pain, refractory Lyme arthritis seems reasonable, but then, this study warns of systemic arthritis after a Lyme disease infection.
When methotrexate fails in rheumatoid arthritis, the next-line treatment is usually a TNF-α inhibitor. But if this treatment fails as well, what's next?
Age and cumulative glucocorticoid exposure are key risk factors for low bone mineral density in systemic lupus erythematosus.
Bone loss could affect as many as 31 percent of SLE patients. This article sums up the treatment options from first-line bisphosphonate recommendations to emerging treatments like abaloparatide.
Doctors, remember that pain is subjective and may not fall easily into a grading system, writes Dr. Irina Litvin, a rheumatology fellow at SUNY Downstate in Brooklyn, N.Y.
All patients about to undergo surgery should be preoperatively evaluated for fall history, a study shows.
Low protein intake may be responsible for fractures in older men, according to an observational study.
Using biomarkers to assess drug efficacy could pave the way for improved osteoporosis treatment, according to a new study.
Assessing the elevated risk of aortic aneurysm in rheumatoid arthritis.
A retrospective analysis of patient records has found a significant link between psoriatic arthritis and malignant cancer – particularly breast cancer.
Tumor necrosis factor inhibitors have transformed the treatment of psoriatic arthritis. However, switching TNF inhibitors two or three times is not uncommon.
Epidemiological evidence points to an intimate relationship between intestinal inflammation and joint inflammation, such as psoriatic arthritis.
The authors say that for uveitis “there is a large unmet medical need" for identifying other therapies. Adalimumab is associated with decreased visual impairment and decreased risk of uveitic flare, but more adverse events, according the results from a recent multinational phase 3 trial.
